Tony Hunt
Vorstandsvorsitzender bei REPLIGEN CORPORATION
Vermögen: 30 Mio $ am 30.04.2024
Profil
Derzeit ist Tony J. Hunt President, Chief Executive Officer & Director bei Repligen Corp. Zuvor war Tony J. Hunt als Senior Director-Pharma Programs bei Applied Biosystems, Inc. und als President-Bioproduction bei Life Technologies Corp. tätig. Tony J. Hunt erhielt einen Undergraduate-Abschluss und einen Graduate-Abschluss von der National University of Ireland und einen MBA von der Questrom School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
REPLIGEN CORPORATION
0,33% | 18.03.2024 | 183 249 ( 0,33% ) | 30 Mio $ | 30.04.2024 |
908 DEVICES INC.
0,03% | 19.04.2024 | 8 886 ( 0,03% ) | 49 406 $ | 30.04.2024 |
Aktive Positionen von Tony Hunt
| Unternehmen | Position | Beginn |
|---|---|---|
| REPLIGEN CORPORATION | Vorstandsvorsitzender | 21.05.2015 |
| 908 DEVICES INC. | Direktor/Vorstandsmitglied | 02.03.2022 |
Ehemalige bekannte Positionen von Tony Hunt
| Unternehmen | Position | Ende |
|---|---|---|
Life Technologies Corp.
 Life Technologies Corp. Miscellaneous Commercial ServicesCommercial Services Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA. | Corporate Officer/Principal | 01.01.2014 |
Applied Biosystems, Inc.
 Applied Biosystems, Inc. Medical SpecialtiesHealth Technology Applied Biosystems, Inc. is a company that provides integrated systems for sequencing, flow cytometry, and various types of PCR. The company is based in Foster City, CA. The company's products cover the entire process from sample preparation to data analysis. The company was founded by Chris Yoo, Marvin H. Caruthers, Michael W. Hunkapiller, and Leroy E. Hood. Applied Biosystems was acquired by Invitrogen Corp. from Applera Corp. on November 21, 2008 for $6,417.85 million. | Corporate Officer/Principal | 01.01.2008 |
Ausbildung von Tony Hunt
| National University of Ireland | Graduate Degree |
| Questrom School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| REPLIGEN CORPORATION | Health Technology |
| 908 DEVICES INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Life Technologies Corp.
Life Technologies Corp. Miscellaneous Commercial ServicesCommercial Services Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA. | Commercial Services |
Applied Biosystems, Inc.
Applied Biosystems, Inc. Medical SpecialtiesHealth Technology Applied Biosystems, Inc. is a company that provides integrated systems for sequencing, flow cytometry, and various types of PCR. The company is based in Foster City, CA. The company's products cover the entire process from sample preparation to data analysis. The company was founded by Chris Yoo, Marvin H. Caruthers, Michael W. Hunkapiller, and Leroy E. Hood. Applied Biosystems was acquired by Invitrogen Corp. from Applera Corp. on November 21, 2008 for $6,417.85 million. | Health Technology |
